New treatment approach for overcoming resistance in breast cancer
CDK7 inhibitors as a new strategy to overcome treatment resistance in ER+ metastatic breast cancer
This study is looking at a new treatment option for people with estrogen receptor positive metastatic breast cancer who aren't responding to usual hormone therapies, using a special medication that might help overcome the resistance caused by certain mutations.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10683956 on NIH RePORTER |
What this research studies
This research focuses on developing a new treatment strategy for patients with estrogen receptor positive (ER+) metastatic breast cancer who have developed resistance to standard endocrine therapies. The study investigates the use of CDK7 inhibitors, which may help to overcome the resistance caused by specific mutations in the estrogen receptor. By targeting these mutations, the research aims to improve treatment outcomes for patients who have exhausted other options. The approach combines laboratory studies with clinical insights to identify effective therapies for this challenging condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with ER+ metastatic breast cancer who have shown resistance to current endocrine therapies.
Not a fit: Patients with early-stage breast cancer or those who have not yet undergone endocrine therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option that improves survival rates for patients with resistant ER+ metastatic breast cancer.
How similar studies have performed: Other research has shown promising results with similar approaches targeting resistance mechanisms in breast cancer, indicating potential for success in this area.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Jeselsohn, Rinath M. — Dana-Farber Cancer Inst
- Study coordinator: Jeselsohn, Rinath M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.